Dienogest
This report and retrospective study identified significant risk factors for malignant transformation of ovarian endometrioma during dienogest treatment.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
The paper reported a case and conducted a retrospective study to identify significant risk factors associated with malignant transformation of ovarian endometrioma during dienogest treatment. Across the included cases, it highlighted factors considered important for transformation while documenting clinical course during dienogest use. The major limitation is that the evidence is based on a single case report plus retrospective data, which constrains causal inference and generalizability. This paper is centrally about endometriosis — it specifically examines malignant transformation risk in ovarian endometrioma during dienogest therapy.
Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works
Full text
532 characters
· extracted from
oa-doi-fallback
· click to expand
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (1)
References (1)
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- unpaywall
- last seen: 2026-08-08T06:39:30.753600+00:00